Beta-Alanine Supplementation for PTSD Resilience

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for post-traumatic stress disorder (PTSD) are limited in preventing or increasing resilience to the condition, and there is a need for effective dietary supplements that can improve physiological responses related to PTSD.

Innovation Solution

Supplementation with the free amino acid beta-alanine, or its salt, administered over a period of time to increase brain carnosine concentrations and maintain brain-derived neurotrophic factor (BDNF) expression, thereby reducing PTSD-like behaviors and symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for PTSD are used, then existing therapeutic options are provided, but effectiveness in preventing or increasing resilience to PTSD is limited

Engineering Contradiction:
Improveeffectiveness of PTSD treatmentVSAvoidresilience to PTSD
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the chemical parameter by introducing beta-alanine supplementation to increase brain carnosine concentrations. This parameter change (increased carnosine levels) leads to improved physiological responses and increased resilience to PTSD symptoms, thereby resolving the contradiction between treatment effectiveness and adaptability.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If beta-alanine is supplemented over a period of time, then brain carnosine concentrations increase and BDNF expression is maintained, but the supplementation requires continuous administration

Engineering Contradiction:
Improvebrain carnosine concentrationVSAvoidsupplementation duration
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by administering beta-alanine supplementation before PTSD symptoms fully develop or worsen. By maintaining brain carnosine concentrations through advance supplementation, the treatment prevents the need for more intensive interventions later, thereby resolving the contradiction between achieving reliable brain carnosine levels and minimizing time loss.

Inventive Principle:
Principle #10Preliminary action

3Ease of operation

If beta-alanine supplementation is administered, then anxiety and PTSD-like behaviors are reduced, but the mechanism involves complex neurochemical changes including BDNF expression and serotonin concentration changes

Engineering Contradiction:
Improvereduction of anxiety and PTSD behaviorsVSAvoidneurochemical mechanism complexity
Core Design Contradiction:
Ease of operationVSDevice complexity

Solution Approach 1:

The patent uses brain carnosine as an intermediary substance that mediates the effect of beta-alanine supplementation on PTSD symptoms. Beta-alanine increases brain carnosine concentrations, which in turn maintains BDNF expression and modulates serotonin concentrations, ultimately reducing anxiety and PTSD-like behaviors. This intermediary mechanism simplifies the operational approach while managing the underlying neurochemical complexity.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The beta-alanine supplementation effectively increases brain carnosine levels and maintains BDNF expression, leading to reduced anxiety, improved behavioral performance, and increased resilience to PTSD-like behaviors in animal models.

Implementation Method 1

when consumed in sufficient dosages over time, β-alanine combines in the skeletal muscle with L-histidine to form the dipeptide carnosine (beta-alanylhistidine)

Methodology Applied
Scientific EffectDipeptide formation: Chemical Bonding

Implementation Method 2

The primary role of carnosine is in the maintenance of acid-base homeostasis through enhanced intra-muscular hydrogen ion (H+) buffering

Methodology Applied
Scientific EffectBuffering: Absorption (physical)

Implementation Method 3

recent research has demonstrated that β-alanine can increase carnosine concentrations in the brain resulting in a decrease in serotonin concentrations, increase brain-derived neurotrophic factor

Methodology Applied
Scientific EffectNeurotransmitter modulation:

Implementation Method 4

Carnosine's biological role as an antioxidant, an antiglycating and ion-chelating agent suggests that it may have a potential role in neuroprotection during oxidative stress

Methodology Applied
Scientific EffectAntioxidant activity: Oxidation

Data Source

PatentEP3261632B1Dietary supplementation for improving physiological responses related to post-traumatic stress disorder
Publication Date: 2019.07.31 NATURAL ALTERNATIVES INTERNATIONAL INC
  • EP3261632B1 patent drawingFigure 1A~1B
  • EP3261632B1 patent drawingFigure 1C~1D
  • EP3261632B1 patent drawingFigure 2A

AI summary

The present invention provides methods of improving physiological responses related to post-traumatic stress disorder, wherein the free amino acid beta-alanine, or a salt or ester thereof, is administered to an individual as a human dietary supplement over a period of time in an amount effective to improve physiological responses related to post-traumatic stress disorder.